Table 2

Associations between CYP17 genotype and breast cancer according to menopausal status at diagnosis of the case patient

A1/A1A1/A2A2/A2A1/A2 and A2/A2
All
Cases, n (%)199 (41.5)227 (47.4)53 (11.1)280 (58.5)
Controls, n (%)200 (41.7)220 (45.8)60 (12.5)280 (58.3)
OR (95% CI)a1.00.96 (0.71–1.28)0.79 (0.50–1.26)b0.92 (0.69–1.22)
Menopausal status at diagnosis
Premenopausal
Cases, n (%)77 (47.2)71 (43.6)15 (9.2)  86 (52.8)
Controls, n (%)88 (43.3)88 (43.3)27 (13.3)115 (56.7)
OR (95% CI)a1.00.87 (0.54–1.39)0.63 (0.30–1.32)b0.81 (0.52–1.27)
Postmenopausal
Cases, n (%)122 (38.6)156 (49.4)38 (12.0)194 (61.4)
Controls, n (%)112 (40.4)132 (47.7)33 (11.9)165 (59.6)
OR (95% CI)a1.01.00 (0.68–1.48)0.98 (0.53–1.80)b1.00 (0.69–1.45)
  • a Adjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, and postmenopausal use of estrogen.

  • b P for trend: all, 0.228; premenopausal, 0.381; postmenopausal, 0.961.